Fairvalue-Calculator Fairvalue-Calculator
EN DE

Sysmex Corporation (SSMXY) Fair Value & Analysis

Healthcare · US · Market cap $5.3B

Price$8.40
Fair Value$9.16
Upside+9.0%
Quality97/100
Evidence: High Range $6.17 – $11.75

Analysis

Sysmex Corporation (SSMXY) currently trades at $8.40, while our model-based Fair Value estimate is $9.16 — implying the stock looks roughly 9.0% undervalued today. We read business quality at 97/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.

About the company

Sysmex Corporation engages in the development, manufacture, and sale of diagnostic instruments, reagents, and related software. It offers non-clinical blood testing and cell analysis for hematology, such as XN-V series, a software for laboratory animal corresponding to XN series fully automated hematology analyzers; XN-Series, a fully automated flagship hematology analyzers; and Automated hematology analyzer ProCyte Dx for Research applications, a housed in a compact body that simultaneously measures five types of leukocytes and reticulocyte counts; coagulation, blood gas/ electrolyte/ urinalysis, cells/ microorganisms, including particle counter/analyzer CDA-1000/1000B, an equipment which is capable of counting cells, yeast, algae, bacteria, and others. The company serves national and other public hospitals, general hospitals, universities, research institutes, other medical institutions, etc. The company was formerly known as TOA Medical Electronics Co., Ltd. and changed its name …

Open the full interactive analysis →

Similar stocks

Abbott Laboratories, (ABTT34) -20% Stryker Corporation (S1YK34) -45% Medtronic plc (MDT) -27% Boston Scientific Corporation (B1SX34) -5% Edwards Lifesciences Corporation (EW) -52% Siemens Healthineers AG (SEMHF) +11%

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.